Hisamitsu Pharmaceutical Co., Inc. is scheduled to be delisted as of May 11, 2026. The share consolidation will consolidate 23,467,182 shares into 1 share, reducing the number of issued shares to 3. The tender offer price is 6,082 yen per share, with the tender offeror holding 61.81% of the shares.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4530","jir_company_name":"Hisamitsu Pharmaceutical Co., Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-03-13","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/03\/4530-20260313-01.pdf","jir_short_summary":"Hisamitsu Pharmaceutical Co., Inc. is scheduled to be delisted as of May 11, 2026. The share consolidation will consolidate 23,467,182 shares into 1 share, reducing the number of issued shares to 3. The tender offer price is 6,082 yen per share, with the tender offeror holding 61.81% of the shares.","jir_summary":"### Overview of Share Consolidation and Privatization\nHisamitsu Pharmaceutical Co., Inc. plans to hold an extraordinary general meeting of shareholders on April 17, 2026, to propose agenda items including share consolidation, abolition of the determination of the number of shares per trading unit, and partial amendment to the articles of incorporation. The share consolidation will consolidate 23,467,182 shares into 1 share, reducing the total number of issued shares to 3. Consequently, it is expected that the shares will be delisted from the Tokyo Stock Exchange Prime Market, Nagoya Stock Exchange Premier Market, and Fukuoka Stock Exchange Main Market as of May 11, 2026.\n\n### Background and Terms of the Tender Offer\nThrough the tender offer conducted from January 7 to February 19, 2026, Taiyo Kosan Co., Ltd. acquired 61.81% of the shares. The tender offer price was finally set at 6,082 yen per share, reflecting approximately a 35% premium. The tender offer is part of a Management Buyout (MBO) intending to privatize the company, aiming to mitigate short-term share price decline risks while seeking medium- to long-term corporate value enhancement. The Board of Directors and the independent special committee have confirmed the fairness and appropriateness of the transaction and recommend shareholders to tender their shares.\n\n### Impact on Shareholders and Fractional Share Handling\nDue to the share consolidation, shares held by shareholders other than the tender offeror and non-tendering agreement shareholders will become fractional shares less than one share and are planned to be sold to the tender offeror. The sale price will be based on the tender offer price of 6,082 yen per share, and cash compensation equivalent to the fractional shares will be provided to affected shareholders. A total of 4,763,348 treasury shares are scheduled for cancellation as of May 12, 2026.\n\n### Future Outlook and Management Policy\nFollowing privatization, Mr. Kazue Nakatomi will continue management, promoting the maximization of value for the prescription and OTC pharmaceutical businesses, business transformation, and strengthening overseas expansion. Privatization will reduce the costs associated with maintaining a public listing and enable agile management decisions, aiming for medium- to long-term increase in corporate value.","jir_financial_highlights":"Share Consolidation Ratio: 1 share for every 23,467,182 shares (Reduced from 70,401,547 total issued shares to 3 shares)\nTender Offer Price: 6,082 yen (Approximately 35.16% premium to the Tokyo Stock Exchange Prime Market closing price of 4,500 yen)\nShares Held by Tender Offeror: 43,574,799 shares (Holding ratio of 61.81%)\nTreasury Stock Cancellation Volume: 4,763,348 shares (Scheduled for cancellation as of May 12, 2026)\nScheduled Delisting Date: May 11, 2026 (Designated as a reorganization stock from April 17, 2026 to May 10, 2026)","jir_category":"","jir_hashtags":"#HisamitsuPharmaceutical, #ShareConsolidation, #CapitalPolicy, #MBO, #Delisting","jir_key_figures":"Share Consolidation Ratio: 23,467,182 shares consolidated into 1 share\nTender Offer Price: 6,082 yen per share (approx. 35% premium)\nShares Held by Tender Offeror: 43,574,799 shares (61.81%)\nTreasury Stock Cancellation Volume: 4,763,348 shares (as of May 12, 2026)\nScheduled Delisting Date: May 11, 2026","jir_meta_title":"Hisamitsu Pharmaceutical Announces Share Consolidation and Delisting. Tender Offer Price Set at 6,082 Yen Per Share with 61.81% Acquisition","jir_meta_description":"Hisamitsu Pharmaceutical is scheduled for delisting on May 11, 2026. The share consolidation ratio is 23,467,182 shares into 1 share, with a tender offer price of 6,082 yen reflecting approximately a 35% premium. The tender offeror acquired 61.81% to promote privatization.","jir_og_title":"Hisamitsu Pharmaceutical Announces Share Consolidation and Privatization (Tender Offer Price: 6,082 Yen)","jir_og_description":"By consolidating shares, Hisamitsu Pharmaceutical will reduce its issued shares to 3 and is scheduled for delisting on May 11, 2026. The tender offer price of 6,082 yen offers shareholders a reasonable opportunity to sell.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":8125,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"capital_policy","footnotes":""},"sector":[],"importance":[],"class_list":["post-34654","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n